Sign up Australia
Proactive Investors - Run By Investors For Investors

Phylogica recommences trading after securing funding, shares up 13%

The company recommenced trading today up 13.3% to 3.4 cents per share.
highway sign reading 'funding, next exit'
The funds will be used to deliver a number of milestones over the coming 12 months

Phylogica Ltd (ASX:PYC) has recommenced trading on the ASX today after a successful recapitalisation that involved a $9.12 million share placement priced at 3 cents.

Firm commitments for the placement funds have been received which will be used to accelerate its path towards first in human trials of its Cell Penetrating Peptides (CPPs).

The placement will occur in two tranches with the first tranche of $4.4 million to be complete on 21 September 2018.

READ: Phylogica achieves a milestone in intracellular drug delivery

Phylogica is using its peptide library to develop a drug delivery platform capable of reaching the highest value drug targets located inside cells.

The company’s drug delivery platform transports drugs into the intracellular environment where most diseases are.

The company aims to find drugs that can get delivered into that intracellular environment and be the delivery mechanism for that drug.

Clear strategy for building shareholder value

Over the next 12 months Phylogica aims to deliver:

- Second generation CPPs from the recently enriched peptide libraries;
- Evaluation of the ability of CPPs to deliver a drug cargo in a therapeutic model of disease (animal model); and
- Initiation of the enabling studies required to lodge an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA).

View full PYC profile View Profile

Phylogica Limited Timeline

Newswire
October 06 2015
Newswire
November 25 2014

Related Articles

Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
cough
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use